Citius Pharmaceuticals Inc (CTXR)

06:32 AM

Citius Pharmaceuticals elects board members and ratifies auditor at annual meeting - investing.com

06:32 AM

05:21 AM

Citius Pharmaceuticals Announces 2026 Annual Stockholder Meeting Results - TipRanks

05:21 AM

04:15 AM

Shareholders keep Citius (NASDAQ: CTXR) board and approve Wolf as auditor - stocktitan.net

04:15 AM

Apr 04, 2026

CTXR SEC FilingsCitius Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - stocktitan.net

Apr 04, 2026

Apr 03, 2026

CTXR Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 03, 2026

Apr 02, 2026

Breakouts Watch: What is Citius Pharmaceuticals Incs 5 year growth outlookTrade Risk Report & Fast Entry and Exit Trade Plans - baoquankhu1.vn

Apr 02, 2026

Apr 01, 2026

CTOR Stock Price, Quote & Chart | CITIUS ONCOLOGY INC (NASDAQ:CTOR) - ChartMill

Apr 01, 2026

Mar 31, 2026

Citius Oncology highlights early LYMPHIR commercial traction, expansion - TipRanks

Mar 31, 2026

Mar 31, 2026

Citius Oncology advances LYMPHIR launch and global expansion - TipRanks

Mar 31, 2026

Mar 31, 2026

Bond Watch: Is Citius Pharmaceuticals Inc in a long term uptrend2026 Performance Recap & Technical Pattern Recognition Alerts - baoquankhu1.vn

Mar 31, 2026

Mar 31, 2026

Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development - Finviz

Mar 31, 2026

Mar 31, 2026

Citius Pharmaceuticals subsidiary reports strong early uptake and broad payer coverage for LYMPHIR launch - TradingView

Mar 31, 2026

Mar 31, 2026

Citius Oncology (CTXR) details early LYMPHIR launch uptake and $400M CTCL market - stocktitan.net

Mar 31, 2026

Mar 31, 2026

Early LYMPHIR launch traction at Citius Oncology (Nasdaq: CTOR) - stocktitan.net

Mar 31, 2026

Mar 31, 2026

Cancer centers move LYMPHIR onto formularies as coverage reaches 80% - stocktitan.net

Mar 31, 2026

Mar 31, 2026

Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development - Sahm

Mar 31, 2026

Mar 30, 2026

Citius Pharmaceuticals Inc (47N0.MU) balance sheet - Yahoo Finance UK

Mar 30, 2026

Mar 29, 2026

RSI Check: Is Citius Pharmaceuticals Inc stock good for income investors2026 Sector Review & High Accuracy Swing Entry Alerts - baoquankhu1.vn

Mar 29, 2026

Mar 28, 2026

Citius Pharmaceuticals Inc (47N0.MU) recent insider transactions - Yahoo Finance UK

Mar 28, 2026

Mar 28, 2026

Rate Hike: Is Citius Pharmaceuticals Inc a cyclical or defensive stock2026 News Drivers & Low Risk Entry Point Guides - baoquankhu1.vn

Mar 28, 2026

Mar 27, 2026

CTXR Stock Price, Quote & Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill

Mar 27, 2026

Mar 24, 2026

Citius Pharmaceuticals to present CTCL clinical experience at USCLC Annual Workshop - tradersunion.com

Mar 24, 2026

Mar 24, 2026

Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts - BioSpace

Mar 24, 2026

Mar 24, 2026

Citius Oncology to Participate in USCLC Annual Workshop 2026, Hi - GuruFocus

Mar 24, 2026

Mar 24, 2026

Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts - Finviz

Mar 24, 2026

Mar 23, 2026

Aug Mood: Can Citius Pharmaceuticals Inc withstand a market correctionEarnings Beat & Long-Term Growth Plans - baoquankhu1.vn

Mar 23, 2026

Mar 22, 2026

Downgrade Watch: Is Citius Pharmaceuticals Inc benefiting from interest rate changesPortfolio Gains Summary & Fast Gain Stock Tips - baoquankhu1.vn

Mar 22, 2026

Mar 22, 2026

If You Invested $1,000 in Citius Pharmaceuticals Inc (CTXR) - stocktitan.net

Mar 22, 2026

Mar 22, 2026

Macro Review: Should I buy Citius Pharmaceuticals Inc stock nowSell Signal & Growth Oriented Trading Recommendations - baoquankhu1.vn

Mar 22, 2026

Mar 20, 2026

Citius Oncology inks exclusive European distribution pact with Uniphar - MSN

Mar 20, 2026

Mar 20, 2026

Ideas Watch: Is Euroholdings Ltd stock trending bullishEarnings Recap Report & Weekly High Return Stock Opportunities - baoquankhu1.vn

Mar 20, 2026

Mar 20, 2026

Energy Moves: Does Citius Pharmaceuticals Inc align with a passive investing strategyMarket Trend Summary & AI Driven Price Forecasts - baoquankhu1.vn

Mar 20, 2026

Mar 18, 2026

D Boral Capital maintains Citius Pharmaceuticals (CTXR) buy recommendation - MSN

Mar 18, 2026

Mar 18, 2026

Activity Recap: Is Citius Pharmaceuticals Inc a potential multi baggerIPO Watch & Stepwise Trade Execution Plans - baoquankhu1.vn

Mar 18, 2026

Mar 17, 2026

CTORCitius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan

Mar 17, 2026

Mar 17, 2026

Activity Recap: Is Citius Pharmaceuticals Inc stock good for income investors2026 Historical Comparison & AI Forecast Swing Trade Picks - baoquankhu1.vn

Mar 17, 2026

Mar 13, 2026

Zevra Therapeutics, Inc.Common Stock (NQ: ZVRA - The Chronicle-Journal

Mar 13, 2026

Mar 11, 2026

CTXR: Citius Pharmaceuticals Receives Consistent 'Buy' Rating fr - GuruFocus

Mar 11, 2026

Mar 11, 2026

Citius Oncology reports positive phase 1 trial data for LYMPHIR By Investing.com - ca.investing.com

Mar 11, 2026

Mar 10, 2026

Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - Finviz

Mar 10, 2026

Mar 10, 2026

Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - BioSpace

Mar 10, 2026

Mar 10, 2026

Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data - TipRanks

Mar 10, 2026

Mar 10, 2026

Citius Oncology reports positive phase 1 trial data for LYMPHIR - Investing.com

Mar 10, 2026

Mar 10, 2026

LYMPHIR combo shows activity in gynecologic cancers for Citius (CTXR) - Stock Titan

Mar 10, 2026

Mar 09, 2026

Market Review: Is Citius Pharmaceuticals Inc in a long term uptrend2026 Trading Recap & Free Weekly Watchlist of Top Performers - baoquankhu1.vn

Mar 09, 2026

Mar 09, 2026

Bull Bear: Is Citius Pharmaceuticals Inc in a long term uptrendPortfolio Risk Summary & Verified Trade Idea Suggestions - baoquankhu1.vn

Mar 09, 2026

Mar 06, 2026

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Mar 06, 2026

Mar 06, 2026

Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR - Yahoo Finance

Mar 06, 2026

Mar 06, 2026

33 Stocks That Should Double in 3 Years - Insider Monkey

Mar 06, 2026

Mar 04, 2026

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma - BioSpace

Mar 04, 2026

Mar 04, 2026

Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data - TipRanks

Mar 04, 2026

Mar 04, 2026

Citius Oncology Announces Positive Phase 1 LYMPHIR Data - TipRanks

Mar 04, 2026

Mar 04, 2026

Phase 1 LYMPHIR data in high-risk DLBCL for Citius Oncology (Nasdaq: CTOR) - stocktitan.net

Mar 04, 2026

Mar 04, 2026

Citius Pharmaceuticals subsidiary reports 86% ORR, 57% CR with LYMPHIR prior to CAR‑T in high‑risk DLBCL - TradingView

Mar 04, 2026

Mar 04, 2026

Citius Oncology (Nasdaq: CTXR) reports encouraging early LYMPHIR CAR-T combo results - Stock Titan

Mar 04, 2026

Mar 04, 2026

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma – Company Announcement - Financial Times

Mar 04, 2026

Feb 28, 2026

CTXR Should I Buy - Intellectia AI

Feb 28, 2026

Feb 27, 2026

Citius Pharmaceuticals CEO Leonard Mazur pursues growth through regulatory partnerships and rare disease therapies - Traders Union

Feb 27, 2026